See more : Lixte Biotechnology Holdings, Inc. (LIXT) Income Statement Analysis – Financial Results
Complete financial analysis of NEXGEL, Inc. (NXGLW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NEXGEL, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Azure Power Global Limited (AZREF) Income Statement Analysis – Financial Results
- Universal Security Instruments, Inc. (UUU) Income Statement Analysis – Financial Results
- CENAQ Energy Corp. (CENQ) Income Statement Analysis – Financial Results
- Cantex Mine Development Corp. (CTXDF) Income Statement Analysis – Financial Results
- CHOTHANI FOODS LIMITED (CHOTHANI.BO) Income Statement Analysis – Financial Results
NEXGEL, Inc. (NXGLW)
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It provides facemasks, undereye patches, blister shield foot care, hexagel, cracked heel repair patches, and fever patch. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was founded in 1997 and is based in Langhorne, Pennsylvania.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 4.09M | 2.05M | 1.55M | 674.00K | 717.00K | 2.21M | 1.99M | 2.15M |
Cost of Revenue | 3.47M | 1.79M | 1.54M | 965.00K | 854.00K | 1.70M | 1.85M | 2.27M |
Gross Profit | 619.00K | 256.00K | 9.00K | -291.00K | -137.00K | 514.00K | 147.00K | -114.00K |
Gross Profit Ratio | 15.14% | 12.50% | 0.58% | -43.18% | -19.11% | 23.23% | 7.38% | -5.30% |
Research & Development | 103.00K | 367.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 3.02M | 2.38M | 2.54M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 620.00K | 436.00K | 320.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.64M | 3.24M | 2.54M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
Other Expenses | 0.00 | 3.00K | 13.00K | 8.00K | 0.00 | 0.00 | 0.00 | 25.00K |
Operating Expenses | 4.10M | 3.60M | 2.58M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
Cost & Expenses | 7.57M | 5.40M | 4.12M | 2.93M | 2.64M | 4.10M | 2.96M | 4.02M |
Interest Income | 0.00 | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 15.00K | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 443.00K | 301.00K | 113.00K | 50.00K | 67.00K | 322.00K | 316.00K | 324.00K |
EBITDA | -2.73M | -3.11M | -2.20M | -2.20M | -1.86M | -1.57M | -653.00K | -1.54M |
EBITDA Ratio | -66.76% | -148.63% | -158.41% | -326.71% | -259.00% | -70.76% | -32.78% | -71.56% |
Operating Income | -3.48M | -3.35M | -2.57M | -2.26M | -1.92M | -1.89M | -969.00K | -1.86M |
Operating Income Ratio | -85.03% | -163.48% | -165.70% | -335.31% | -268.34% | -85.31% | -48.64% | -86.62% |
Total Other Income/Expenses | 289.00K | -1.40M | -1.74M | -4.00K | 1.00K | 0.00 | 0.00 | 25.00K |
Income Before Tax | -3.19M | -4.75M | -4.31M | -2.26M | -1.92M | -1.89M | -969.00K | -1.84M |
Income Before Tax Ratio | -77.97% | -231.74% | -277.89% | -335.91% | -268.20% | -85.31% | -48.64% | -85.46% |
Income Tax Expense | 0.00 | 1.40M | 2.00M | 18.00K | -104.86K | 160.86K | -16.00K | -63.00K |
Net Income | -3.16M | -6.14M | -6.31M | -2.28M | -1.92M | -1.89M | -953.00K | -1.78M |
Net Income Ratio | -77.21% | -300.00% | -406.71% | -338.58% | -268.20% | -85.31% | -47.84% | -82.53% |
EPS | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
EPS Diluted | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
Weighted Avg Shares Out | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
Weighted Avg Shares Out (Dil) | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
Source: https://incomestatements.info
Category: Stock Reports